Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > The Private Market for Tuberculosis… >
The Private Market for Tuberculosis Drugs

Published: May 5, 2011.
By GCI Health- TB Alliance

(May 4, 2011, NEW YORK, USA) Tuberculosis (TB) is widely considered a public health concern and its treatment a public sector responsibility. But according to a study published today in the journal PLoS ONE, the private sector for TB treatment is ignored at our peril. Across 10 high-burden countries, there is as much TB drug volume in the private sector as in the public sector—and at least a third of all private sector dosages of first-line TB drugs fall outside of national and international treatment recommendations. Any resulting drug misuse could be responsible for many treatment failures and for escalating the emergence of multidrug-resistant TB (MDR-TB), which is further worsening the TB epidemic.

The research, conducted by the TB Alliance and IMS Health (a healthcare market research and consulting-services firm), is the first detailed study of the private TB drug market across multiple high-burden countries. Sixty percent of the world's TB burden is present in the 10 study countries (Bangladesh, China, India, Indonesia, Pakistan, Philippines, Russian Federation, South Africa, Thailand, and Viet Nam).

TB treatment requires lengthy, supervised treatment to maximize cure rates and minimize the development of drug resistance, and in low-income settings this task is thought to be more achievable in the public sector. By contrast, the private sector treatment landscape in these countries is largely unregulated and fragmented; for example, the study detected 111 different first-line TB drug dosages and combinations, compared to the 14 deemed necessary by the Stop TB Partnership's Global Drug Facility.

"The private sector is keeping alive the confusion that existed previously in the public sector," said Dr. William Wells, the study's lead author and Director of Market Access at the TB Alliance. "With this new baseline understanding of the TB drug market, we can no longer ignore the private sector's critical role in the access equation for TB treatment and in the task of protecting both current drugs and new regimens from the development of resistance."

Other key findings revealed that:

  • The public and private sectors are both major channels of treatment for TB patients. Nearly equal amounts of TB drugs are dispensed in the public and private sectors (enough to treat 67 percent vs. 66 percent of estimated incidence, respectively). The size of the private sector for TB drugs varies between countries, but has been steady within most countries over the past 5 years.

  • Four of the biggest high-burden countries – India, Indonesia, Pakistan, and Philippines – had particularly large private sectors. Enough TB drugs are sold in their private sectors to treat all, or nearly all, incident TB patients with a full TB drug regimen. This is without even considering the 60 to 80 percent coverage by the public sector.

  • Few patients receive MDR-TB treatment in the public sector—and the data reveal that the private sector is not stepping in to fill the gap. Private sector sales have the capacity to cover only ~1-10% of MDR-TB patients (or 0%, in three study countries) with anything approaching a full regimen. However, with new, rapid diagnostics becoming available, this market may expand rapidly, thus highlighting the urgency for action now.

"During the past decade, the world has seen a reawakening of TB drug development efforts, and the first wave of new TB treatments will be introduced within the next few years," said Dr. Mel Spigelman, President and CEO of the TB Alliance. "This study fills a critical gap in our knowledge base."

"Most countries covered in this study have public-private mix (PPM) programmes for TB care," said Mario Raviglione, Director of the Stop TB Department at the World Health Organization. "Based on country experiences, these programmes have shown good results in optimizing TB management by private care providers. However, the size of the response is not commensurate with the size of the challenge; there is enormous scope to expand these programmes urgently. Private providers following best practices should be supported through accreditation and access to free TB drugs from the public sector, while those not doing so should be regulated. Greater government and international support is needed for these efforts and also for improved regulatory oversight and quality assurance of TB drugs. A dual track approach of collaboration and regulation is the logical way forward. We ought to make private providers responsible partners of the public sector in controlling TB and MDR-TB".




Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the ScienceNewsline.
Related »

Primary 
8/30/11 
Optimal Reperfusion in ST-elevation Myocardial Infarction
By European Society of Cardiology
Primary PCI is the best reperfusion therapy for patients presenting with acute ST-elevation myocardial infarction. CJ Terkelsen and co-workers used the Western Denmark Heart Registry to describe the implementation …
Pci 
1/28/13 
Public Report National Audit of Percutaneous Coronary Interventional Procedures 2011
By University College London
The 2011 annual report of the National Audit of Percutaneous Coronary Intervention (PCI) highlights the significant progress within hospitals to expand PCI services to treat more patients with acute …
Sickness 
2/22/11 
New Face of Sleeping Sickness Epidemiology Highlights Need for New Tools
By Public Library of Science
Recent developments have rekindled hopes of eliminating human African trypanosomiasis (HAT), more familiarly known as sleeping sickness, as a public health problem in those areas of sub-Saharan Africa where …
Patients 
7/2/13 
Treating TB: What Needs to Be Done to Improve Treatment Rates
By BioMed Central
People with tuberculosis (TB) in China often delay going to see a doctor for more than two weeks, finds research in BioMed Central's open access journal BMC Medicine. Reasons …
Treatment 
4/1/11 
Importance of Policy Action to Help Reduce HCV-related Deaths Across Europe by 2025
By European Association for the Study of the Liver
New findings from two modeling studies presented at the International Liver Congress support the call to action from medical experts and patients in relation to the challenge health inequalities …
Treatment 
11/16/10 
New Dry Powder Antibiotic Targets Tuberculosis, Reduces Treatment Time
By American Association of Pharmaceutical Scientists
Arlington, Va. — New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) …
More » 

Most Popular - Medicine »
TUMORS »
The Immune System's Redesigned Role in Fighting Cancerous Tumors
LOS ANGELES (March 11, 2014) – Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. …
IRON »
Study: Iron Consumption Can Increase Risk for Heart Disease
MARIJUANA »
Casual Marijuana Use Linked to Brain Abnormalities in Students
CHICAGO --- Young adults who used marijuana only recreationally showed significant abnormalities in two key brain regions that are important in emotion and motivation, scientists report. The study was …
INFLUENZA »
Ginseng Can Treat And Prevent Influenza And RSV, Researcher Finds
ATLANTA--Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist …
PROTEINS »
MSU Physicists Push New Parkinson's Treatment Toward Clinical Trials
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.